692. Genome Editing for Personalized Gene Therapy of IVSI 110 Beta Thalassemia
Thalassemia is amongst the commonest single gene disorders worldwide, caused by deficient production of a or b globin. Of particular clinical relevance is b thalassemia, which as a severe monogenic disease of the hematopoietic system is an ideal target for gene therapy, either by gene addition or gene correction. Problems inherent to the gene augmentation approach for b thalassemia, including insertional mutagenesis or low expression of the therapeutic transgene, may be avoided using targeted gene correction of mutations with site specific designer nucleases, such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 or transcription activator like effector nucleases (TALENs) Our study is focused on the development of a personalized gene correction therapy of the common b thalassemia mutation, HBBIVS1 110, which in most Mediterranean and many Western countries has a frequency of above 20% (with 80% on the island of Cyprus) amongst b thalassemia carriers. HBBIVS1 110 creates an abnormal splice acceptor site in intron I of the b globin gene, leading to a pre mature in frame stop codon in the aberrantly spliced mRNA and to early transfusion dependence of homozygotes. We have developed and evaluated designer nucleases targeting the site of the HBBIVS1 110 b thalassemia mutation, including direct comparison of targeted disruption efficiency and toxicity for CRISPR/Cas9 and TALEN tools in human embryonic kidney cells and in murine erythroleukemia (MEL) cells carrying a HBBIVS1 110mutant transgene based on the GLOBE (MA821) vector. Using the latter, we have assessed the therapeutic efficiency and cleavage properties of these designer nucleases. Analyses included immunoblots, absolute quantification of correctly and aberrantly spliced HBB mRNAs using multiplex RT qPCR, sequencing and characterization of the resulting genome editing events. We noted superior performance of several TALEN pairs compared to a single CRISPR/Cas9 nuclease suitable for the target site. Moreover, we demonstrate a significant increase of correct splicing and b globin chain synthesis for genome edited transgenic MEL MA821 HBBIVS1 110 cells. For the two most efficient TALEN pairs, b globin protein levels in pools of edited cells reach over 20% of that detected in MEL cells harbouring a wild type MA821 HBB control, up from 1% for the mock treated MA821 HBBIVS1 110 control. Our findings validate our approach and indicate its suitability also for the correction of other intronic disease causing mutations.